Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Thoracic 1Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 491Lung Neoplasms 208Adenocarcinoma of Lung 49Small Cell Lung Carcinoma 34Neoplasms 31Adenocarcinoma, Bronchiolo-Alveolar 25Neoplasm Metastasis 20Breast Neoplasms 20Ovarian Neoplasms 19Colorectal Neoplasms 16Carcinoma 14Squamous Cell Carcinoma of Head and Neck 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Melanoma 13Carcinoma, Ovarian Epithelial 12Stomach Neoplasms 11Carcinoma, Renal Cell 9Head and Neck Neoplasms 8Respiratory Tract Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Endometrial Neoplasms 7Thoracic Neoplasms 6Pleural Effusion, Malignant 6Lung Diseases 6Esophageal Neoplasms 6Colonic Neoplasms 6Carcinoma, Squamous Cell 6Adenocarcinoma 6Non-Squamous Non-Small Cell Lung Cancer 5

Interventions

Pemetrexed 2Carboplatin 2durvalumab 1Tretinoin 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Gemcitabine 1Cisplatin 1Bortezomib 1Azacitidine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Paclitaxel × Thoracic × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡